ClinicalTrials.gg
Active, not recruitingNCT05668013Updated Nov 12, 2026

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

A Phase 2 interventional study of TEV-48574 Dose Regimen A and TEV-48574 Dose Regiment B in Crohn Disease and Colitis, Ulcerative, sponsored by Teva Branded Pharmaceutical Products R&D LLC. Active, not recruiting at 93 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Teva Branded Pharmaceutical Products R&D LLC (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Updated Nov 12, 2026Study completion moved93 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 161 studies in Crohn Disease with a site in Poland — 34 open to participants now, 51 under way, 32 of them phase 3. Crohn Disease · Poland.

Enrollment
69th of 152
247 · median 192
Started
2023
with 9 others
Phase 2
56 of 161
8 open now
Primary completion
2026-01
later than 5 of 50 live
Registered
120th of 161
by date

Among the 161 studies in Crohn Disease with a site in Poland, this one is the 69th largest by enrollment of the 152 interventional ones that give a count, is one of 10 that started in 2023, is one of 56 in phase 2, reaches primary completion later than 5 of the 50 other live ones, and was the 120th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

34 of the 161 studies in Crohn Disease with a site in Poland are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Crohn Disease with a site in Poland, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD).

Secondary objectives of the study are to:

  • evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD
  • evaluate the safety and tolerability of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD
  • evaluate the immunogenicity of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD

The total duration for a participant in the double-blind period only is 66 weeks; and for a participant in the open-label extension (OLE) period, up to an additional 268 weeks.

03

Conditions studied

  • Crohn Disease
  • Colitis, Ulcerative
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Maintenance Period- Participants who achieved clinical response and/or clinical remission at week 14 of TV48574-IMM-20036 (the 14-week DRF study) or in the re-induction period of this study.
  • Re-induction- Participants who did not achieve clinical response and/or clinical remission at week 14 of the TV48574-IMM-20036 DRF study

NOTE- Additional criteria may apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • Participants who discontinued the TV48574-IMM-20036 study before scheduled week 14 visit (any reason including lack of efficacy, safety, or personal reasons)
  • Participant has any concomitant conditions or treatments that could interfere with study conduct, influence the interpretation of study observations/results, or put the participant at increased risk during the study as judged by the investigator and/or the clinical study physician.
  • Participant anticipates requiring major surgery during this study.
  • Participant is currently pregnant or lactating or is planning to become pregnant or to lactate during the study or for at least 50 days after administration of the last dose of IMP in case of early termination. Any woman becoming pregnant during the study will be withdrawn from the study.

NOTE- Additional criteria apply, please contact the investigator for more information

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    TEV-48574 Dose Regimen A for Ulcerative Colitis (UC)

    Administered by subcutaneous infusion for participants with UC

    Drug: TEV-48574 Dose Regimen A

  • Experimental
    TEV-48574 Dose Regimen A for Crohn's Disease (CD)

    Administered by subcutaneous infusion for participants with CD

    Drug: TEV-48574 Dose Regimen A

  • Experimental
    TEV-48574 Dose Regimen B for Ulcerative Colitis (UC)

    Administered by subcutaneous infusion for participants with UC

    Drug: TEV-48574 Dose Regiment B

  • Experimental
    TEV-48574 Dose Regimen B for Crohn's Disease (CD)

    Administered by subcutaneous infusion for participants with CD

    Drug: TEV-48574 Dose Regiment B

Interventions

  • Subcutaneous (sc) administration using a commercial sc infusion system

    Also known as: duvakitug

  • Subcutaneous (sc) administration using a commercial sc infusion system

    Also known as: duvakitug

06

What researchers measure

Primary outcomes

  1. Number of participants with moderate to severe ulcerative colitis (UC) who show clinical remission as defined by the Mayo score

    Clinical remission based on modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of ≤2 points, which is defined by: * stool frequency subscore of 0 or 1, * rectal bleeding subscore of 0, and * endoscopic subscore of 0 or 1, where a score of 1 does not include "friability"

    Time frame: Week 44

  2. Number of participants with moderate to severe Crohn's disease (CD) who show an endoscopic response as defined by the Endoscopic Score for Crohn's Disease

    Endoscopic response, defined as a decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) of at least 50% from DRF study baseline at week 44 in participants with CD

    Time frame: Week 44

Secondary outcomes

  1. Number of participants with moderate to severe UC with a clinical response as defined by Mayo score

    Clinical response at week 44, defined as a decrease from baseline in the modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of at least 2 points AND at least a 30% reduction from DRF baseline with either a decrease in rectal bleeding subscore of at least 1 or an absolute rectal bleeding subscore of less than or equal to 1

    Time frame: Week 44

  2. Number of participants with moderate to severe UC with Endoscopic improvement as defined by Mayo score

    Endoscopic improvement defined as a Mayo endoscopic subscore of 0 or 1

    Time frame: Week 44

  3. Number of participants with moderate to severe UC in Endoscopic remission as defined by Mayo score

    Endoscopic remission defined as a Mayo endoscopic subscore of 0

    Time frame: Week 44

  4. Number of participants with moderate to severe UC with Corticosteroid-free clinical remission based on the modified Mayo score

    Defined by clinical remission and corticosteroid-free for ≥12 weeks preceding week 44

    Time frame: Week 44

  5. Number of participants with moderate to severe CD with a clinical response based on Crohn's Disease Activity Index

    Clinical response defined as a ≥100-point decrease from DRF baseline Crohn's Disease Activity Index (CDAI) score

    Time frame: Week 44

  6. Number of participants with moderate to severe CD in clinical remission as defined by CDAI score

    Clinical remission defined as a CDAI score less than 150

    Time frame: Week 44

  7. Number of participants with moderate to severe CD with Corticosteroid-free endoscopic response based on SES-CD

    Defined by endoscopic response and corticosteroid-free for ≥12 weeks preceding week 44

    Time frame: Week 44

  8. Number of participants with moderate to severe CD with Corticosteroid-free clinical remission based on CDAI

    Defined by a CDAI score of \<150 points and corticosteroid-free for ≥12 weeks preceding week 44

    Time frame: Week 44

  9. Number of participants who experience adverse events in the double-blind period

    Adverse events can include any of the following clinically significant changes in clinical laboratory test results (serum chemistry, hematology, and urinalysis), vital signs measurements (blood pressure, pulse rate, body temperature, and respiratory rate), 12-lead electrocardiogram (ECG), and injection site reactions.

    Time frame: Up to Week 48

  10. Number of participants who experience adverse events in the open-label (OL) period

    Adverse events can include any of the following clinically significant changes in clinical laboratory test results (serum chemistry, hematology, and urinalysis), vital signs measurements (blood pressure, pulse rate, body temperature, and respiratory rate), 12-lead electrocardiogram (ECG), and injection site reactions.

    Time frame: Up to 5 years after start of OL period

  11. Number of participants who stopped taking the investigational medicinal product (IMP) due to adverse events in the double-blind period

    Time frame: Up to Week 48

  12. Number of participants who stopped taking the investigational medicinal product (IMP) due to adverse events in the open-label (OL) period

    Time frame: Up to 5 years after start of OL period

  13. Number of participants with treatment emergent Anti-Drug Antibodies (ADA)

    Time frame: Weeks 0, 4, 8, 16, 28, 44, and 48

  14. Number of ADA positive participants with the presence of neutralizing ADA

    Time frame: Weeks 0, 4, 8, 16, 28, 44, and 48

07

Study locations

93 sites
08

References and documents

Publications

  • Solitano V, Jairath V, Ungaro F, Peyrin-Biroulet L, Danese S. TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis. Med. 2024 May 10;5(5):386-400. doi: 10.1016/j.medj.2024.03.010. Epub 2024 Apr 3. PubMed 38574740 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Jan 2026, 35 months.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 35 months is close to that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2031 → Jan 2027, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Dec 29, 2022
StartActual
Jan 11, 2023
Primary completionActual
Jan 5, 2026
CompletionEst.
Jan 31, 2027was Mar 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
93 sites added, 93 sites removed
Show 93 added (31 Poland, 18 United States, 8 Ukraine, 5 Japan, 5 Slovakia, 4 Germany, 3 Bulgaria, 3 Czechia, 3 Hungary, 3 Italy, 3 Spain, 2 Georgia, 2 Israel, 1 Austria, 1 Norway, 1 United Kingdom)
  • Clinical Applications Laboratories Inc · San Diego, United States
  • I.H.S. Health · Kissimmee, United States
  • Endoscopic Research, Inc. · Orlando, United States
  • Gastro Florida · Pinellas Park, United States
  • Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee · Gurnee, United States
  • Gastroenterology Health Partners, PLLC · New Albany, United States
  • University of Kansas Medical Center · Kansas City, United States
  • Gastroenterology Health Partners, PLLC - Central Louisville · Louisville, United States
  • BVL Clinical Research · Liberty, United States
  • Washington University School of Medicine · St Louis, United States
  • Vector Clinical Trials · Las Vegas, United States
  • Dayton Gastroenterology, LLC - Beavercreek · Beavercreek, United States
  • Texas Digestive Specialists · Harlingen, United States
  • Gastro Health & Nutrition - Katy · Katy, United States
  • Gastroenterology Research of San Antonio LLC · San Antonio, United States
  • Texas Digestive Disease Consultants, PLLC. dba GI Alliance - Southlake · Southlake, United States
  • Tyler Research Institute, LLC · Tyler, United States
  • Care Access · Salt Lake City, United States
  • Medical University Vienna · Vienna, Austria
  • Multiprofile Hospital For Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD · Gorna Oryahovitsa, Bulgaria
  • 20th Diagnostic Consultancy Center, Sofia · Sofia, Bulgaria
  • University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic, Sofia · Sofia, Bulgaria
  • Military Hospital Brno · Brno, Czechia
  • GASTRO JeKa s.r.o. · Klatovy, Czechia
  • Hospital Slany · Slaný, Czechia
  • Israeli - Georgian Medical Research Clinic Healthycore LLC · Tbilisi, Georgia
  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC · Tbilisi, Georgia
  • University Hospital Schleswig-Holstein · Kiel, Germany
  • University Hospital Tuebingen · Tübingen, Germany
  • University Hospital Ulm · Ulm, Germany
  • …and 63 more on the registry record
Show 93 removed
  • Teva Investigational Site 15556 · San Diego, United States
  • Teva Investigational Site 15357 · Kissimmee, United States
  • Teva Investigational Site 15375 · Orlando, United States
  • Teva Investigational Site 15359 · Pinellas Park, United States
  • Teva Investigational Site 15567 · Gurnee, United States
  • Teva Investigational Site 15574 · New Albany, United States
  • Teva Investigational Site 15367 · Kansas City, United States
  • Teva Investigational Site 15575 · Louisville, United States
  • Teva Investigational Site 15358 · Liberty, United States
  • Teva Investigational Site 15373 · St Louis, United States
  • Teva Investigational Site 15369 · Las Vegas, United States
  • Teva Investigational Site 15750 · Beavercreek, United States
  • Teva Investigational Site 15559 · Harlingen, United States
  • Teva Investigational Site 15366 · Katy, United States
  • Teva Investigational Site 15374 · San Antonio, United States
  • Teva Investigational Site 15565 · Southlake, United States
  • Teva Investigational Site 15361 · Tyler, United States
  • Teva Investigational Site 15364 · Salt Lake City, United States
  • Teva Investigational Site 33056 · Vienna, Austria
  • Teva Investigational Site 59243 · Gorna Oryahovitsa, Bulgaria
  • Teva Investigational Site 59197 · Sofia, Bulgaria
  • Teva Investigational Site 59196 · Sofia, Bulgaria
  • Teva Investigational Site 54221 · Brno, Czechia
  • Teva Investigational Site 54222 · Klatovy, Czechia
  • Teva Investigational Site 54220 · Slaný, Czechia
  • Teva Investigational Site 81052 · Tbilisi, Georgia
  • Teva Investigational Site 81053 · Tbilisi, Georgia
  • Teva Investigational Site 32793 · Kiel, Germany
  • Teva Investigational Site 32795 · Tübingen, Germany
  • Teva Investigational Site 32794 · Ulm, Germany
  • …and 63 more on the registry record
Nov 12, 2026
Study completion
Mar 8, 2031→Jan 31, 2027
Oct 6, 2026
Show all 2 updates
  1. Nov 12, 2026
    93 sites added, 93 sites removed
    Show 93 added (31 Poland, 18 United States, 8 Ukraine, 5 Japan, 5 Slovakia, 4 Germany, 3 Bulgaria, 3 Czechia, 3 Hungary, 3 Italy, 3 Spain, 2 Georgia, 2 Israel, 1 Austria, 1 Norway, 1 United Kingdom)
    • Clinical Applications Laboratories Inc · San Diego, United States
    • I.H.S. Health · Kissimmee, United States
    • Endoscopic Research, Inc. · Orlando, United States
    • Gastro Florida · Pinellas Park, United States
    • Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee · Gurnee, United States
    • Gastroenterology Health Partners, PLLC · New Albany, United States
    • University of Kansas Medical Center · Kansas City, United States
    • Gastroenterology Health Partners, PLLC - Central Louisville · Louisville, United States
    • BVL Clinical Research · Liberty, United States
    • Washington University School of Medicine · St Louis, United States
    • Vector Clinical Trials · Las Vegas, United States
    • Dayton Gastroenterology, LLC - Beavercreek · Beavercreek, United States
    • Texas Digestive Specialists · Harlingen, United States
    • Gastro Health & Nutrition - Katy · Katy, United States
    • Gastroenterology Research of San Antonio LLC · San Antonio, United States
    • Texas Digestive Disease Consultants, PLLC. dba GI Alliance - Southlake · Southlake, United States
    • Tyler Research Institute, LLC · Tyler, United States
    • Care Access · Salt Lake City, United States
    • Medical University Vienna · Vienna, Austria
    • Multiprofile Hospital For Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD · Gorna Oryahovitsa, Bulgaria
    • 20th Diagnostic Consultancy Center, Sofia · Sofia, Bulgaria
    • University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic, Sofia · Sofia, Bulgaria
    • Military Hospital Brno · Brno, Czechia
    • GASTRO JeKa s.r.o. · Klatovy, Czechia
    • Hospital Slany · Slaný, Czechia
    • Israeli - Georgian Medical Research Clinic Healthycore LLC · Tbilisi, Georgia
    • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC · Tbilisi, Georgia
    • University Hospital Schleswig-Holstein · Kiel, Germany
    • University Hospital Tuebingen · Tübingen, Germany
    • University Hospital Ulm · Ulm, Germany
    • …and 63 more on the registry record
    Show 93 removed
    • Teva Investigational Site 15556 · San Diego, United States
    • Teva Investigational Site 15357 · Kissimmee, United States
    • Teva Investigational Site 15375 · Orlando, United States
    • Teva Investigational Site 15359 · Pinellas Park, United States
    • Teva Investigational Site 15567 · Gurnee, United States
    • Teva Investigational Site 15574 · New Albany, United States
    • Teva Investigational Site 15367 · Kansas City, United States
    • Teva Investigational Site 15575 · Louisville, United States
    • Teva Investigational Site 15358 · Liberty, United States
    • Teva Investigational Site 15373 · St Louis, United States
    • Teva Investigational Site 15369 · Las Vegas, United States
    • Teva Investigational Site 15750 · Beavercreek, United States
    • Teva Investigational Site 15559 · Harlingen, United States
    • Teva Investigational Site 15366 · Katy, United States
    • Teva Investigational Site 15374 · San Antonio, United States
    • Teva Investigational Site 15565 · Southlake, United States
    • Teva Investigational Site 15361 · Tyler, United States
    • Teva Investigational Site 15364 · Salt Lake City, United States
    • Teva Investigational Site 33056 · Vienna, Austria
    • Teva Investigational Site 59243 · Gorna Oryahovitsa, Bulgaria
    • Teva Investigational Site 59197 · Sofia, Bulgaria
    • Teva Investigational Site 59196 · Sofia, Bulgaria
    • Teva Investigational Site 54221 · Brno, Czechia
    • Teva Investigational Site 54222 · Klatovy, Czechia
    • Teva Investigational Site 54220 · Slaný, Czechia
    • Teva Investigational Site 81052 · Tbilisi, Georgia
    • Teva Investigational Site 81053 · Tbilisi, Georgia
    • Teva Investigational Site 32793 · Kiel, Germany
    • Teva Investigational Site 32795 · Tübingen, Germany
    • Teva Investigational Site 32794 · Ulm, Germany
    • …and 63 more on the registry record
    + 1 other change: verification date
  2. Oct 6, 2026
    Study completion Mar 8, 2031→Jan 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05668013
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Dec 29, 2022
Start date
Jan 11, 2023
Primary completion
Jan 5, 2026
Completion
Jan 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvakitug

Start the discussion